BLA 761400 · Rengeneron Pharmaceuticals, Inc.
Lynozyfic
Linvoseltamab-Gcpt · Injection
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Jul 2, 2025: To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 2, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
7 Phase 3, 17 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 2, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelMedication Guide
1 products under this application
- LYNOZYFIC · LINVOSELTAMAB-GCPT 5MG/2ML · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Linvoseltamab" as an intervention, any sponsor and status, largest first.
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for TransplantPivotal-lookingRecruiting
European Myeloma Network B.V.Research network
NCT06932562 · 1,000 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2036
Drug: Linvoseltamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Adelaide, Australia; Box Hill, Australia; Canberra, Australia · 59 sites in all
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07222761 · 915 participants (planned) · Start Jan 2, 2026 · Primary completion May 21, 2029
Drug: Linvoseltamab; Carfilzomib and 4 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Atlanta, Georgia; Ann Arbor, Michigan; New York, New York · 60 sites in all
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMPivotal-lookingRecruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07624513 · 720 participants (planned) · Start Aug 31, 2026 · Primary completion Oct 1, 2033
Drug: Isatuximab; Iberdomide and 4 more · For: Multiple Myeloma
Sites: Boston, Massachusetts · 3 sites in all
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05730036 · 410 participants (planned) · Start Sep 18, 2023 · Primary completion Apr 19, 2033
Drug: Linvoseltamab; Elotuzumab and 2 more · For: Relapsed Refractory Multiple Myeloma (RRMM)
Sites: Los Angeles, California; Gainesville, Florida; Lexington, Kentucky · 159 sites in all
- BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.Pivotal-lookingNot yet recruiting
Anne Louise Tølbøll SørensenAcademic, hospital or other
NCT07474961 · 400 participants (planned) · Start Mar 2027 · Primary completion Dec 2036
Drug: teclistamab OR talquetamab OR elranatamab OR linvoseltamab; BTK inhibitors (ibrutinib and zanubrutinib) · For: Waldenstrom Macroglobulinaemia; Multiple Myeloma
Sites: Copenhagen, Denmark; Aalborg, Denmark; Aarhus, Denmark · 5 sites in all
- Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03761108 · 387 participants (planned) · Start Jan 23, 2019 · Primary completion Mar 30, 2033
Drug: Linvoseltamab · For: Multiple Myeloma
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 40 sites in all
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07901725 · 382 participants (planned) · Start Dec 18, 2026 · Primary completion Jul 25, 2035
Drug: Linvoseltamab; Daratumumab and 3 more · For: Newly Diagnosed Amyloidosis; Amyloidosis Stage I-IIIA
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05137054 · 317 participants (planned) · Start Aug 17, 2022 · Primary completion Mar 25, 2028
Drug: Linvoseltamab; Daratumumab and 9 more · For: Multiple Myeloma
Sites: La Jolla, California; Atlanta, Georgia; Indianapolis, Indiana · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
Kumar S, Jagannath S, Weisel KC, et al. · Blood Cancer J 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Richter J, Lee HC, Jagannath S, et al. · Leuk Lymphoma 2026 · Clinical Trial, Comparative Study
- Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
Kumar S, Weisel KC, Spin P, et al. · Blood Cancer J 2026 · Clinical Trial, Phase II, Clinical Trial, Phase I
- T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.
Shambhavi S, Joy AA, Singh H, et al. · Int J Mol Sci 2026 · Systematic Review, Network Meta-Analysis
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.
Hoffman JE, Bumma N, Richter J, et al. · Blood Neoplasia 2026 · Clinical Trial
Sponsor: Rengeneron Pharmaceuticals, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.